BioTech Navigator Investment Newsletter News 3 98 Page 7
7
BioTech Navigator, March 1998
EPS Fiscal Year
1997 1998(E)
Product
Indication
Clinical Stage
-1.11
1
-1.93
Betafectin-Oral
Chronic resistant infections
Lead
2.35 2.63
Neupogen
Community-acquired pneumonia
Phase lll
3.22 3.63
Maxipime
Bacterial Infections
Marketed
-.73 -.78
Daptomycin
Bacterial Infections
Preclinical
-.57
1
-.79
ProTox
Drug-resistant tuberculosis
IND filed
-1.59 -1.99
DepoAmikacin
Bacterial Infections
Phase l
-1.05 -1.02
P483 Techtide
Image internal infection
Phase ll
1.16
2
1.78
Sanfetrinem
Bacterial Infections
Phase ll
-.45
3
NA
Diagnostics for Staph aureus
Bacterial Infections
Preclinical
-.32
1
NA
LeukoScan
Bacterial Infections
App Submitted
-.73 -.84
Cytolex
Infections in diabetic foot ulcers
Phase lll
-1.59 -1.51
StaphVAX
Bacterial infections
R & D
-.43 -.47
Beta-lactam compound for cephalosporin
Infection - Antibiotics
Preclinical
-.83
1
.16
MiKasome
Drug-resistant Tuberculosis
Phase ll
-.95 .19
Vaccine for group B Streptococcus
Infection in newborns
Phase l
-.04 .19
StaphVAX
Staphyloccus aureus vaccine
Phase ll
.01 1.72
Tobi
P.aeruginosa infections in cystic fibrosis
Phase lll
1.41 1.67
U-100766
Bacterial Infections
Phase ll
1.66 2.02
Trovafloxacin
Bacterial Infections
Marketed
-.32 -.17
Adjuvants
Bacterial Infections
Phase l/ll/lll
5.62 (FF) NA
Synercid
Bacterial Infections
Phase lll
-.78 -.15
STEALTH platform
Bacterial Infections
R & D
-.66
1
-.10
Vaccine
Strep Throat
Preclinical
-.44 NA
Neuprex
Bacterial Infections
Phase ll
1. 3 qtrs. for 1997
2. 3 qtrs. for 1998
3. 2 qtrs. for 1997
